March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
2 citations
,
December 2004 in “PubMed”
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
32 citations
,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
1 citations
,
July 2022 in “Frontiers in Pharmacology” Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
98 citations
,
April 1997 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively blocks rat enzymes, but with varying methods and strength.
April 2021 in “Anatolian current medical journal :” A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
January 2023 in “Cutaneous and Ocular Toxicology”